AmorChem backs project aimed at treating cystic fibrosis, COPD
AmorChem has entered into a collaboration with Traffick Therapeutics Inc co-founders and McGill University researchers Dr David Y. Thomas and Dr. John W. Hanrahan. The focus of the project is to develop novel small molecules which could be used in the treatment of cystic fibrosis and chronic obstructive pulmonary disease. AmorChem’s medicinal chemistry group, NuChem Therapeutics Inc, will participate in the project work. Based in Montréal, AmorChem is an early stage life sciences fund managed by Canadian venture capital firm GeneChem.
20 June 2014•4 mins read
